Novo Nordisk shares slide as Trump vows to cut Ozempic price
US administration is in negotiations over cost of Danish group’s best-selling obesity drug
Related reading
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Trump administration slashes Ozempic and Wegovy price for Medicare
US negotiates 71% cost reduction of Novo Nordisk’s obesity drugs for elderly Americans on government health insurance
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
US to slash prices of obesity drugs offered on Trump website
White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment